Mihaela Munteanu

发表

Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study

A. Balar, P. Grivas, M. S. van der Heijden, 2024, BMC cancer.

Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study

B. Cirauqui, R. Swaby, J. Ge, 2024, BMC cancer.

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study

A. Peer, R. Kataria, R. Leibowitz, 2024, BMC cancer.

KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non–small-cell lung cancer

M. Satouchi, K. Yoh, M. Nishio, 2024, Investigational new drugs.